Cargando…

Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance

Detalles Bibliográficos
Autores principales:	Hescot, Ségolène, Masliah-Planchon, Julien, du Rusquec, Pauline, Dupain, Célia, Kamal, Maud, Servois, Vincent, Bieche, Ivan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578058/ https://www.ncbi.nlm.nih.gov/pubmed/36053791 http://dx.doi.org/10.1530/ETJ-22-0044

Ejemplares similares

Fine‐needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next‐generation sequencing in cancer patients included in the SHIVA02 trial
por: Dupain, Célia, et al.
Publicado: (2020)

Pralsetinib treatment for multiple RET fusions in lung adenocarcinoma: a case report
por: Cao, Xiangming, et al.
Publicado: (2022)

Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report
por: Meng, Yan, et al.
Publicado: (2022)

Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report
por: Gu, Linping, et al.
Publicado: (2022)

Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report
por: Wu, Ying, et al.
Publicado: (2022)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
por: Subbiah, V., et al.
Publicado: (2020)

Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
por: Gao, Ming, et al.
Publicado: (2023)

Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation
por: Zhao, Jing, et al.
Publicado: (2023)

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
por: Zhou, Ning, et al.
Publicado: (2022)

RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
por: Zhang, Tongyi, et al.
Publicado: (2023)

A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring KIF5B-RET Fusion Responds to First-Line Pralsetinib Treatment: A Case Report
por: Qin, Hao, et al.
Publicado: (2023)

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
por: Shen, Tao, et al.
Publicado: (2021)

Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma
por: Debbabi, Inès, et al.
Publicado: (2023)

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report
por: Zhao, Zichen, et al.
Publicado: (2022)

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma
por: Nannini, Margherita, et al.
Publicado: (2022)

Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC
por: An, Li, et al.
Publicado: (2022)

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
por: d'Arienzo, Paolo D., et al.
Publicado: (2023)

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
por: Wang, Sha-Sha, et al.
Publicado: (2022)

Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
por: Wang, Sha-Sha, et al.
Publicado: (2022)

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
por: Subbiah, Vivek, et al.
Publicado: (2022)

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
por: Jeon, Youngkyung, et al.
Publicado: (2023)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
por: Højer Wang, Linnea, et al.
Publicado: (2023)

Results and Clinical Interpretation of Germline RET Analysis in a Series of Patients with Medullary Thyroid Carcinoma: The Challenge of the Variants of Uncertain Significance
por: Innella, Giovanni, et al.
Publicado: (2020)

Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET
por: Sahakian, Nicolas, et al.
Publicado: (2023)

Allel RET+3 : T a medullary thyroid cancer
por: Pławski, A, et al.
Publicado: (2011)

A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
por: Petak, Istvan, et al.
Publicado: (2021)

De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor
por: Morel, Adeline, et al.
Publicado: (2019)

Into the Unknown: A Case of New-Onset Cardiomyopathy in a Patient Treated With Recently Approved Tyrosine Kinase Inhibitor, Pralsetinib
por: Papaila, Alexa, et al.
Publicado: (2021)

Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Al Khayat, Mohamed N. M. T., et al.
Publicado: (2023)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
por: Huang, Qin, et al.
Publicado: (2020)

Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
por: Vaflard, Pauline, et al.
Publicado: (2021)

Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET Polymorphisms
por: Ceolin, Lucieli, et al.
Publicado: (2011)

Clinical significance of variants of unknown significances in BRCA genes
por: Choi, Min Chul
Publicado: (2019)

RET mutations in a large indian family with medullary thyroid carcinoma
por: Mahesh, D. M., et al.
Publicado: (2014)

RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
por: Romei, Cristina, et al.
Publicado: (2018)

Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma
por: Skalniak, Anna, et al.
Publicado: (2021)

Effect of 3′UTR RET Variants on RET mRNA Secondary Structure and Disease Presentation in Medullary Thyroid Carcinoma
por: Ceolin, Lucieli, et al.
Publicado: (2016)

Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma
por: Mulè, Chiara, et al.
Publicado: (2021)

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer
por: Urbanska, Edyta M., et al.
Publicado: (2022)

Significance of chromogranin A and synaptophysin in medullary thyroid carcinomas
por: Tomita, Tatsuo
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v8kasue3l3rdncq0fi5ic4g0e3